CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Skye Biosciences Expands its Team to Begin Human Trial for Glaucoma and Expand R&D Undertakings

Life Sciences Review Life Sciences Review | Wednesday, November 10, 2021
Tweet

With the team expansion, the business aims at working toward initiating its first-in-human trial for glaucoma and expand its research and development activities.


FREMONT, CA: Expanding the team to pursue meaningful solutions for patients to provide unmet medical needs is vital for most businesses today. In its quest to expand its key capabilities, Skye Bioscience, a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Rhea Williams, MPH, as Head of Regulatory Affairs and Quality Assurance and Varun Khurana, Ph.D., as Senior Director of Research & Development to its management team.


Rhea has a background in medication development, regulatory relations, and quality assurance spanning over 25 years. In the fields of neurology, hematology, oncology, women’s health, cardiology, and ophthalmology, she has supported the creation of small and large molecules and worked with teams focusing on serious and life-threatening disorders and prospective treatments. “I look forward to working with the team to implement a comprehensive regulatory strategy to develop its promising drug candidates to their full medical potential,” said Rhea.


“We have been conservative in our organizational growth, but intentional with adding vital roles and the right people at the right time. 


We also value pertinent experience in developing cannabinoid pharmaceuticals. Our team expansion with these skilled individuals is a strategic step as we work to initiate our first-in-human trial for glaucoma and expand our research and development activities,” said Punit Dhillon, CEO of Skye Bioscience. “We welcome Rhea and Dr. Khurana to Skye. We expect their proven track records and deep expertise to make an immediate impact on our development efforts.”


Dr. Khurana has extensive experience in pre-formulation and formulation development, technical transfer, CMC, CMO/CRO management, and regulatory submissions for unique and complicated drug development programs, with over seven years of experience. Product ideation, portfolio planning, due diligence, lifecycle management, and intellectual property strategy are among his specialties. Dr. Khurana has experience in ophthalmic, injectable, oral, and sublingual dosage forms.


Khurana commented, “I am excited to join Skye at such a pivotal time of growth and innovation for the company. I believe Skye is at the forefront of unlocking the pharmaceutical value of cannabinoid-based therapies and I look forward to driving Skyes R&D strategy to further grow its pipeline and build a well-differentiated and sustainable portfolio.”


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/skye-biosciences-expands-its-team-to-begin-human-trial-for-glaucoma-and-expand-rd-undertakings-nwid-627.html